tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Christopher Marai, 191 are a BUY (82.33%), 33 are a HOLD (14.22%), 8 are a SELL (3.45%).
Analyst Christopher Marai, carries an average stock price target met ratio of 54.96% that have a potential upside of 64.05% achieved within 406 days. Previously, Christopher Marai worked at PIPER SANDLER, NOMURA, RAYMOND JAMES, OPPENHEIMER, BAIRD.
Christopher Marai’s has documented 467 price targets and ratings displayed on 29 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on BIIB, Biogen at 29-Apr-2025.
Analyst best performing recommendations are on SRPT (SAREPTA THERAPEUTICS).
The best stock recommendation documented was for DCPH (DECIPHERA PHARMACEUTICALS LLC) at 10/23/2017. The price target of $57 was fulfilled within 31 days with a profit of $36.21 (174.17%) receiving and performance score of 56.18.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 15-May-2025
$400
$128.23 (47.18%)
$473
10 days ago
(22-Jul-2026)
10/11 (90.91%)
$133.01 (49.82%)
28
Buy Since 21-Nov-2019
$410
$138.23 (50.86%)
$462
18 days ago
(14-Jul-2026)
14/18 (77.78%)
$128.74 (45.77%)
151
Buy Since 21-Jul-2025
$410
$138.23 (50.86%)
$505
19 days ago
(13-Jul-2026)
4/8 (50%)
$121.94 (42.33%)
11
Hold Since 24-Feb-2023
$400
$128.23 (47.18%)
$408
22 days ago
(10-Jul-2026)
11/13 (84.62%)
$101.24 (33.89%)
37
Buy Since 21-Mar-2025
$380
$88.63 (30.42%)
$583
2 months 13 days ago
(19-May-2026)
33/35 (94.29%)
$85.7 (29.12%)
270
What Year was the first public recommendation made by Christopher Marai?
